A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

@article{Kontopodis2016API,
  title={A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer},
  author={Emmanouel Kontopodis and Athanasios A Kotsakis and Nikolaos Kentepozidis and Kostas Syrigos and Nikolaos Ziras and Michalis Moutsos and Gianluca Filippa and Anna Mala and Lambros Vamvakas and Dimitrios Mavroudis and Vassilis Georgoulias and Sofia I Agelaki},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2016},
  volume={77},
  pages={949-956}
}
Bortezomib is a selective reversible proteasome inhibitor with proapoptotic effects. Preclinical and phase I clinical data suggest activity of bortezomib in NSCLC, either as monotherapy or in combination with chemotherapeutic agents including gemcitabine and cisplatin. Chemotherapy-naïve patients with inoperable stage IIIB or IV NSCLC were administered bortezomib 1 mg/m2 i.v. on days 1 and 8, and starting on day 21 (cycle 2), bortezomib (days 1 and 8) in combination with gemcitabine 1000 mg/m2… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2009
View 3 Excerpts

A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors

J Voortman, EF Smit, +3 authors G Giaccone
ECCO • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…